Galapagos Initiates IBD Therapy Trial on Ulcerative Colitis Patients

Galapagos Initiates IBD Therapy Trial on Ulcerative Colitis Patients
glpg-300Galapagos NV has started a phase 2 Proof-of-Concept study to evaluate a potential novel therapy, a GPR84 inhibitor called GLPG1205 that is being studied in patients who suffer from ulcerative colitis. The experimental therapy has been developed as part of a target discovery platform designed by Galapagos and is fully proprietary, according to a company press release. The phase 2 Proof-of-Concept clinical trial for GLPG1205 will include about 60 participants with moderate to severe ulcerative colitis, in order to assess the therapy's efficacy, safety, tolerability and pharmacokinetics, as well as to understand its effects on selected biomarkers in the UC patient population. Therefore, the patients will be administrated either 100 mg of GLPG1205 or placebo once every day for twelve weeks. The primary endpoint taken into consideration in the study will be alterations in Mayo scores compared to baseline at the eight weeks, which will be confirmed with endoscopy to measure the improvement of the disease. Galapagos is recruiting patients in Belgium, Hungary, Czech Republic, Germany, Poland and Russia, and has already received full approvals to do so in the first four countries, while the last two should be approved during the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *